Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone

The efficacy and safety of abiraterone acetate in patients with high-risk prostate cancer: a meta-analysis based on six randomized control trials

Translational Andrology and Urology ◽

10.21037/tau-20-1058 ◽

2020 ◽

Vol 9 (4) ◽

pp. 1691-1699

Author(s):

Guobin Tan ◽

Zijun Xuan ◽

Zhiqin Li ◽

Shuitong Huang ◽

Guangming Chen ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Meta Analysis ◽

Abiraterone Acetate ◽

Randomized Control Trials ◽

Efficacy And Safety ◽

Risk Prostate Cancer ◽

Randomized Control

Effects of preoperative abiraterone acetate (AA) plus enzalutamide (E) and leuprolide acetate (LHRHa) versus AA and LHRHa in localized high-risk prostate cancer (LHRPC).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5061 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5061-5061 ◽

Cited By ~ 1

Author(s):

Eleni Efstathiou ◽

Patricia Troncoso ◽

Elsa Li Ning Tapia ◽

John W. Davis ◽

Mark Anton Titus ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Abiraterone Acetate ◽

Leuprolide Acetate ◽

Re: Intense Androgen-Deprivation Therapy with Abiraterone Acetate plus Leuprolide Acetate in Patients with Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study

10.1016/j.juro.2015.03.046 ◽

2015 ◽

Vol 193 (6) ◽

pp. 1983-1983

Author(s):

Samir S. Taneja

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Androgen Deprivation Therapy ◽

Phase Ii ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Leuprolide Acetate ◽

Randomized Phase Ii ◽

Adding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Directly randomised data from STAMPEDE (NCT00268476)

Annals of Oncology ◽

10.1093/annonc/mdx440.024 ◽

2017 ◽

Vol 28 ◽

pp. v619 ◽

Cited By ~ 7

Author(s):

M.R. Sydes ◽

M.D. Mason ◽

M.R. Spears ◽

N.W. Clarke ◽

D. Dearnaley ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Androgen Deprivation Therapy ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

665 EFFECT OF NEOADJUVANT ABIRATERONE ACETATE PLUS LEUPROLIDE ACETATE ON PSA, PATHOLOGIC RESPONSE, AND INTRAPROSTATIC/SERUM ANDROGEN LEVELS IN LOCALIZED HIGH-RISK PROSTATE CANCER: RESULTS OF A RANDOMIZED PHASE 2 STUDY

10.1016/j.juro.2013.02.220 ◽

2013 ◽

Vol 189 (4S) ◽

Author(s):

Jerome P. Richie ◽

Robert B. Montgomery ◽

Christopher J. Logothetis ◽

Glenn J. Bubley ◽

Bruce L. Dalkin ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Abiraterone Acetate ◽

Pathologic Response ◽

Phase 2 ◽

Phase 2 Study ◽

Risk Prostate Cancer ◽

Randomized Phase 2 ◽

Androgen Levels

Total Androgen Blockade Versus a Luteinizing Hormone–Releasing Hormone Agonist Alone in Men With High-Risk Prostate Cancer Treated With Radiotherapy

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2009.03.034 ◽

2010 ◽

Vol 76 (5) ◽

pp. 1439-1444 ◽

Cited By ~ 7

Author(s):

Akash Nanda ◽

Ming-Hui Chen ◽

Brian J. Moran ◽

Michelle H. Braccioforte ◽

Daniel Dosoretz ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Luteinizing Hormone ◽

Luteinizing Hormone Releasing Hormone ◽

Releasing Hormone ◽

Risk Prostate Cancer ◽

Androgen Blockade

MP97-01 EFFICACY OF A NEOADJUVANT LUTEINIZING HORMONE-RELEASING HORMONE ANTAGONIST PLUS LOW-DOSE ESTRAMUSTINE PHOSPHATE IN HIGH-RISK PROSTATE CANCER

10.1016/j.juro.2017.02.3045 ◽

2017 ◽

Vol 197 (4S) ◽

Author(s):

Kazuhisa Hagiwara ◽

Takuya Koie ◽

Yuki Tobisawa ◽

Tohru Yoneyama ◽

Hayato Yamamoto ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Luteinizing Hormone ◽

Low Dose ◽

Estramustine Phosphate ◽

Luteinizing Hormone Releasing Hormone ◽

Releasing Hormone ◽

PD10-09 INTERIM ANALYSIS OF PHASE 2 RANDOMIZED PROSPECTIVE STUDY ON NEOADJUVANT APALUTAMIDE/ABIRATERONE ACETATE WITH PREDNISONE AND THE FEASIBILITY OF PERFORMING NERVE-SPARING RADICAL PROSTATECTOMY IN MEN WITH HIGH-RISK PROSTATE CANCER (NCT02949284)

10.1097/ju.0000000000000844.09 ◽

2020 ◽

Vol 203 ◽

pp. e249

Author(s):

Joshua Sterling* ◽

Kevin Chua ◽

Hiren Patel ◽

Isaac Kim

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Radical Prostatectomy ◽

Prospective Study ◽

Interim Analysis ◽

Abiraterone Acetate ◽

Nerve Sparing ◽

Phase 2 ◽

Neoadjuvant enzalutamide (ENZA) and abiraterone acetate (AA) plus leuprolide acetate (LHRHa) versus AA+ LHRHa in localized high-risk prostate cancer (LHRPC).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.5002 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 5002-5002 ◽

Cited By ~ 6

Author(s):

Eleni Efstathiou ◽

John W. Davis ◽

Mark Anton Titus ◽

Brian Francis Chapin ◽

Amado J. Zurita ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Abiraterone Acetate ◽

Leuprolide Acetate ◽

Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer

European Urology ◽

10.1016/j.eururo.2018.11.022 ◽

2019 ◽

Vol 75 (4) ◽

pp. 676-683 ◽

Cited By ~ 4

Author(s):

Kerri Beckmann ◽

Hans Garmo ◽

Jan Adolfsson ◽

Cecilia Bosco ◽

Eva Johansson ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Gonadotropin Releasing Hormone ◽

Androgen Deprivation ◽

Primary Therapy ◽

Releasing Hormone ◽